In ischemic stroke, IV alteplase within 3 h of onset improves functional outcome vs. control

Area of Science:

• Neurology
• Clinical Trials
• Evidence-Based Medicine

Background:

• Intravenous alteplase is a critical treatment for acute ischemic stroke.
• The robustness of clinical trial evidence can be uncertain.
• The fragility index quantifies the statistical certainty of trial results.

Purpose of the Study:

• To evaluate the evidential strength for the benefit of intravenous alteplase within 3 hours in acute ischemic stroke.
• To apply the fragility index methodology to a meta-analysis of relevant randomized controlled trials.

Main Methods:

• A meta-analysis was conducted on randomized controlled trials (RCTs) investigating intravenous alteplase for stroke.
• The fragility index was calculated for the primary outcome of benefit.
• Statistical significance and the number of studies/patients needed to overturn the conclusion were assessed.

Main Results:

• The meta-analysis demonstrated a highly robust evidential strength for the benefit of < 3-hour intravenous alteplase.
• The calculated fragility index indicated substantial statistical certainty supporting this conclusion.
• The findings suggest that the observed benefit is unlikely to be due to chance or small, unobserved studies.

Conclusions:

• The evidence supporting the early administration of intravenous alteplase (within 3 hours) for acute ischemic stroke is statistically robust.
• The fragility index confirms the high degree of certainty in this therapeutic recommendation.
• This strengthens the clinical guideline for timely thrombolytic therapy in stroke management.